2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 239

The SELENA SLEDAI Is an Imperfect Measure of Lupus Disease Activity in Patients with Concomitant Fibromyalgia
Abstract Number: 240

Whom Do Patients with Fibromyalgia Turn to for Emotional Support?
Abstract Number: 241

Comparing Patients with Fibromyalgia Syndrome with Non-Fibromyalgia Rheumatic Disease Patients Regarding Exercise
Abstract Number: 242

The Effectiveness of Medications for Fibromyalgia Based on Patient Experiences
Abstract Number: 243

Concomitant Fibromyalgia in Patients with Other Rheumatic Diseases and Response to Treatment
Abstract Number: 244

Real-World Evidence Associated with the Treatment of Systemic Lupus Erythematosus in the USA, UK, France, and Germany: A Structured Review
Abstract Number: 245

Comorbidities, Health Care Utilization, and Cost of Care in Systematic Lupus Erythematous Increase with Disease Severity During 1 Year Before and After Diagnosis: A Real-World Cohort Study in the United States, 2004–2015
Abstract Number: 246

Smoking Exposure in Pack-Years Predicts Cutaneous Manifestations of Lupus
Abstract Number: 247

Health Literacy, Adherence, and Quality of Life of Uveitis Patients
Abstract Number: 248

Adherence to Biologic Disease-modifying Anti-rheumatic Drugs (DMARDs) —a Comparison of Long-term Adherence Among Patients with Various Inflammatory Conditions by Primary Dispensing Channel
Abstract Number: 249

Evaluation of Real-World Early-Line Abatacept versus Tumor Necrosis Factor Inhibitors Persistence in Rheumatoid Arthritis Patients with Anti-Citrullinated Protein Antibody or Rheumatoid Factor Positivity
Abstract Number: 250

Treatment Patterns, Dose Change, and Treatment Discontinuation in RA Patients Switching from First Biologic DMARD to Another Treatment in the US
Abstract Number: 251

Long-term Financial Impact of Switching from Reference to Biosimilar Etanercept When Considering Short-term Formulary Management Costs in the US
Abstract Number: 252

Treatment Sequences, Effectiveness, and Costs of Tumor Necrosis Factor Inhibitor Cycling Compared with Swapping to a Novel Disease-modifying Anti-rheumatic Drug in Rheumatoid Arthritis Patients
Abstract Number: 253

A Systematic Review and Meta-analysis of Observational Studies Reporting on the Use of Checkpoint Inhibitors in Patients with Cancer and Pre-existing Autoimmune Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.